XML 27 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Investments
3 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Investments
Investments

The following table provides information by level for the Company’s marketable securities that were measured at fair value on a recurring basis:
 
 
 
 
Fair Value Measurements as of September 30, 2018
Using Inputs Considered as
 
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
Mutual funds
 
$
505

 
$
179

 
$
326

 
$

  Total short-term investments
 
$
505

 
$
179

 
$
326

 
$

 
 
 
 
Fair Value Measurements as of June 30, 2018
Using Inputs Considered as
 
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
Mutual funds
 
$
544

 
$
199

 
$
345

 
$

  Total short-term investments
 
$
544

 
$
199

 
$
345

 
$



Effective July 1, 2018 the Company adopted the provisions of ASU 2016-01. Unrealized gains and losses of marketable securities previously recognized in other comprehensive income will now be recognized in net income as a component of other income. Upon adoption, the Company recorded a cumulative-effect reclassification adjustment of $101 from accumulated other comprehensive income to the opening balance of retained earnings as of July 1, 2018.

During the three months ended September 30, 2018 and 2017, there were no purchases of marketable securities. There was $51 and $47 of marketable securities that were sold during the three months ended September 30, 2018 and 2017, respectively.

The Company’s marketable securities classified within Level 1 are valued using real-time quotes for transactions in active exchange markets. Marketable securities within Level 2 are valued using readily available pricing sources. There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the three months ended September 30, 2018. Any transfers between levels would be recognized on the date of the event or when a change in circumstances causes a transfer.

The Company holds an equity investment that does not have a readily determined fair value. The Company has elected to measure this investment at cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Impairment is reviewed each reporting period by performing a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. As of September 30, 2018 and June 30, 2018, the carrying value of the investment was $2,538. During the three months ended September 30, 2018, no impairment indicators were noted. The investment is recorded within other long term assets on the consolidated balance sheet.